You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖-B(02315.HK)與Radiance Biopharma達成雙特異性抗體偶聯協定
阿思達克 01-08 16:54
百奧賽圖-B(02315.HK)宣布與生物技術公司Radiance達成一項獨家選擇權與授權協定。該協定使得 Radiance有權選擇獲得一款百奧賽圖同類首創全人HER2/TROP2雙特異性抗體偶聯藥物的授權,用於針對任何人類疾病的治療性產品在全球範圍內的開發、生產和商業化。 HER2和TROP2是兩個腫瘤相關抗原,已被發現在多種腫瘤類型中共表達,包括乳腺癌、胃癌、結直腸癌、膀胱癌、胰腺癌和非小細胞肺癌。 根據協定,如果Radiance行使了選擇權,百奧賽圖將有權獲得選擇權行使費、許可費、開發和商業化里程碑付款,以及個位數淨銷售額分成。此外,如果Radiance再授權給協力廠商,百奧賽圖還將獲得分許可費。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account